Clinical Trials · NCT06046417
A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes
- Phase
- Phase 2/Phase 3
- Recruitment status
- Unknown
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Enrollment
- 30
- Start date
- Nov 2023
- Locations
- 1 site, Canada
- Primary endpoint
- Percentage of time of glucose levels spent in the target range (3.9-10.0 mmol/L).